
In a Community Case Forum in partnership with the North Carolina Oncology Association, Cristina Gasparetto, MD, discussed the CEPHEUS, IMROZ, and BENEFIT trials of treatment for transplant-ineligible newly diagnosed multiple myeloma.

Your AI-Trained Oncology Knowledge Connection!


In a Community Case Forum in partnership with the North Carolina Oncology Association, Cristina Gasparetto, MD, discussed the CEPHEUS, IMROZ, and BENEFIT trials of treatment for transplant-ineligible newly diagnosed multiple myeloma.

In separate, live virtual events, David H. Aggen, MD, PhD; and Matthew R. Zibelman, MD, discussed the case of a patient with urothelial carcinoma and potential treatment options.

Peers & Perspectives in Oncology editorial board member Marc J. Braunstein, MD, PhD, FACP, discussed the significant advancements in multiple myeloma treatment at the 2024 ASH Annual Meeting and Exposition.

During a Case-Based Roundtable® event, Jay Yang, MD, discussed the trial comparing luspatercept with ESA in myelodysplastic syndrome.

During a Case-Based Roundtable® event, Evan J. Lipson, MD, moderated a discussion on the tolerability of immunotherapy in metastatic melanoma and when to stop therapy.

During a Case-Based Roundtable® event, Julie R. Brahmer, MD, MSC, reviewed the CheckMate 9LA, KEYNOTE-407, and POSEIDON trials of immunotherapy in patients with metastatic non–small cell lung cancer.

During a Case-Based Roundtable® event, Nitin Jain, MD, and participants discussed treating a patient with CLL after acalabrutinib and venetoclax/rituximab.

During a Case-Based Roundtable® event, Neeraj Agarwal, MD, and participants discussed how they might determine which combination therapy to use for a patient with metastatic renal cell carcinoma.

During a Case-Based Roundtable® event, Muhammad Umair Mushtaq, MD, discussed managing long-term toxicity concerns related to CAR T-cell therapy in multiple myeloma.